About us
Discover the unique CRISPR screening portfolio developed at Myllia Biotechnology
At Myllia, we make use of different gene editing technologies ranging from CRISPR knockout to CRISPR interference and CRISPR activation applications. We can offer small or genome-wide screens in many different CRISPR-ready cellular models including engineered cancer cell lines and even primary human T cells.
Our CRISPR screens are coupled to advanced read-outs including fitness, flow cytometry, CITE-seq and single-cell transcriptomics (CROP-seq), and we work with clients in the industry, customizing projects specifically to their needs.
Would you like to check out Myllia’s portfolio? Download the intro video here!